局限期小细胞肺癌化疗联合放疗疗效分析

Effect Analysis of Concurrent Chemo-radiotherapy for the Limited-stage Small-cell Lung Cancer

目的回顾分析局限期小细胞肺癌经化疗后放疗再化疗与化疗后同步化放疗再化疗的疗效。方法患者71例,分为化疗4周期后放疗再化疗2周期为A组,24例;化疗2周期后放疗再化疗4周期为B组,22例;化疗2周期后同步放化疗再化疗2周期为C组,25例。化疗为EP方案,放疗为三维适形放疗。治疗后1月判断近期疗效,观察复发进展情况,并随访无进展生存时间(PFS)和总生存时间(OS)。结果 A组、B组和C组有效率分别为75.0%、77.3%和84.0%。三组间差异无统计学意义(P>0.05)。A组、B组和C组中位PFS分别为9月、10月和13月,有统计学意义(P<0.05)。A组、B组和C组中位OS分别为15月、17月和21月,有显著统计学意义(P<0.01)。结论三组近期疗效相似,化疗2周期后同步化放疗再化疗2周期,能够延长局限期小细胞肺癌患者中位无进展生存时间和总生存时间。

Objective To analyze retrospectively tile effect of chemotherapy before sequential chemo-ra- diotherapy or concurrent chemo-radiotherapy, following chemotherapy for patients with limited-stage small-cell lung cancer （SCLC） Methods 71 patients with Limited-stage SCLC were divided into A ,B and C three groups. They were treated with fore-, two, two cycles of induction chemotherapy （ cisplatin plus etoposide） respectively, followed by sequential chemo-radiotherapy or concurrent chemo-radiotherapy and 2 ~ 4 cycles of chemotherapy. The short-term effect was observed after 1 month. The overall and progression-free survival time were also recor- ded. Results Response rate was 75.0% ,77.3% and 84.0% in the group Agroup B,and groupC. There was no difference （ P 〉 0.05 ） between them. Median progression-free survival time and median overall survival time were 9 months, 10 month, 13 months and 15 months, 17 months,21 months in the three groups, respectively. There had significant difference （P 〈 0.01 ） between them. Conclusion Concurrent chemo-radiotherapy can pro- long obviously progression-free survivaltime and overall survivaltime for Limited-staze SCLC.